Palmitoiletanolamida (PEA)

Palmitoylethanolamide (PEA)

1. Identity: Chemical and Botanical Characterization

Palmitoylethanolamide (PEA), chemically named N-(2-hydroxyethyl)-palmitamide, is an endogenous fatty acid amide first isolated and described in 1957. It is also referred to in the scientific literature as N-palmitoylethanolamine and palmidrol, and appears under the brand designations Normast®, PeaPure®, and Levagen+®, among others. PEA (N-palmitoylethanolamine) is an endogenous fatty acid amide belonging to the N-acylethanolamine (NAE) class of signalling molecules.

PEA belongs to the class of non-endocannabinoid N-acylethanolamines (NAEs), which also includes stearoylethanolamide, oleoylethanolamide (OEA), and linoleoylethanolamide. It is a non-endocannabinoid lipid mediator belonging to the NAE phospholipid class, which also includes the first endocannabinoid discovered, N-arachidonoyl-ethanolamine (anandamide; AEA), and the anorectic mediator N-oleoyl-ethanolamine (OEA).

Palmitoylethanolamide is a typical example of a compound belonging to what may be called the "endocannabinoidome," a complex system including several endocannabinoid-like mediators with pharmacological profiles that are often much broader than those of the classical endocannabinoids.

Natural Sources

PEA is naturally present in various common food sources, including soybean lecithin, egg yolk, peanuts, and certain meat products. It is also present in roasted coffee, black-eyed peas, apples, lentils, and potatoes, albeit in small quantities, and is found in human milk.

PEA (C16:0 N-acylethanolamine) is a lipid mediator biologically synthesized in many plants as well as in cells and mammalian tissues. Beyond dietary intake, PEA is synthesized endogenously within mammalian tissues, often produced locally "on demand" in response to cellular stress, injury, or inflammation.

Common Preparations and Dosage Forms

PEA is a poorly water-soluble substance and as such the dissolution rate is often the rate-limiting step for oral absorption and bioavailability. Dissolution rate is influenced by, among other factors, particle size, and therefore drug substances are usually micronized in order to achieve a more rapid dissolution. Compared to naïve PEA (particle size profile ranging between 100 and 700 µm), micronized and ultramicronized PEA differ in their particle size profiles (2–10 µm and 0.8–6 µm at most, respectively).

For oral administration PEA is micronized (mPEA) and/or ultramicronized (umPEA) to increase its bioavailability. The micronization process, by reducing particle size, improves PEA absorption and distribution, increasing its biological efficacy, making it a promising candidate for clinical use. Currently, several PEA-containing formulations are available as nutraceuticals, dietary supplements, or medical foods in various countries; however, the ultra-micronized formulation of PEA alone can cross biological barriers, including the blood–brain barrier, thereby ensuring therapeutically active concentrations.

Since 2008, PEA has been marketed as a food for special medical purposes in Italy and Spain, under the brand name Normast® (Epitech Srl). A food supplement named PeaPure® was also introduced (JP Russell Science Ltd.). In the USA, PEA has been under evaluation as a nutraceutical for inflammatory bowel syndrome (proposed brand name Recoclix, CM&D Pharma Ltd.; Nestlé).

2. Historical and Traditional Use

Early Observations: Egg Yolk and Rheumatic Fever (1943)

The history of PEA extends to the early 1940s, when egg yolk was shown to contribute to the protection against rheumatic fever among poorly nourished children in New York. In 1943, Alvin F. Coburn and Lucile V. Moore discovered an association between egg consumption or supplementation of dried egg yolk and the incidence of rheumatic fever (caused by haemolytic streptococcal infection) in poor New York children. PEA was retrospectively found to be a relevant ingredient in egg yolk; feeding poor children with known streptococcal infections prevented rheumatic fever.

First Isolation and Characterization (1957)

Earliest reports on its immune-modulating properties date back to 1957 when scientists from Merck Sharp & Dohme described its isolation from soy lecithin, peanut meal, and egg yolk and showed it to possess anti-inflammatory activities. This 1957 characterization formally identified the active compound and established its chemical identity, representing the first milestone in PEA's scientific history.

Impulsin® and Eastern European Clinical Use (1960s–1970s)

In former Czechoslovakia, much clinical research was done in the 1960s and 1970s on PEA, formulated as tablets under the brand name Impulsin® (SPOFA United Pharmaceutical Works, Prague, Czechoslovakia). Its immunosupportive effects in influenza, respiratory disorders, and rheumatic fever were described in a number of papers. Interesting preclinical findings fueled this first clinical chapter related to the anti-inflammatory properties of PEA.

Between 1972 and 1977, the period that PEA was available in former Czechoslovakia as an approved drug for oral administration, six different placebo-controlled trials involving in total 3,627 individuals were carried out with the compound. The aim of these studies was to investigate the prophylactic and therapeutic efficacy of PEA against influenza and the common cold. Relevant side effects were not seen at oral doses up to 1800 mg/day.

In 1974, Masek and colleagues published a sequence of placebo-controlled double-blind trials evaluating the use of PEA as a respiratory infection prophylactic in a population of 1,386 volunteers and reported a significant reduction in pain, amount of fever episodes, and incidence of respiratory tract infections. Impulsin® was withdrawn from the market several years later for no apparent reason.

Revival via Nobel Laureate Rita Levi-Montalcini (1993–1996)

The molecule remained largely unnoticed in the rest of the world until in the early 1990s, Nobel Prize laureate Rita Levi-Montalcini proposed that PEA is an endogenously produced regulator of inflammation. The revival of the molecule in the 1990s coincided with the discovery of the endocannabinoid system at that time.

PEA attracted the interest of the scientific community mainly after the discovery by Italian Nobel Prize laureate Rita Levi-Montalcini and co-workers that some acylethanolamides, initially termed ALIA-amides (autacoid local injury antagonist; ALIA), are endogenously synthesized lipids exerting interesting anti-inflammatory properties. This changed in 1993 as a result of the work of Levi-Montalcini, who was awarded the Nobel prize for her work on the role of nerve growth factor (NGF) in inflammation and its activating role in mast cells, showing that positive feedback of NGF on mast cell behavior could be modulated and inhibited by PEA.

3. Key Constituents and Established Mechanisms of Action

Chemical Structure and Endogenous Biosynthesis

PEA is a natural amide of ethanolamine and palmitic acid and is part of the N-acylethanolamine family of bioactive lipids. Endogenous PEA is biosynthesized from the membrane phospholipid N-palmitoyl-phosphatidylethanolamine (NAPE), most prominently via hydrolysis by N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) in neuronal, glial, and immune cells.

Following synthesis, PEA is degraded by fatty acid amide hydrolase (FAAH) or N-acylethanolamine-hydrolysing acid amidase (NAAA). Unlike other endocannabinoids, catabolism of PEA in the body gives rise to relatively inactive products (palmitic acid and ethanolamine), which do not produce adverse effects.

PEA has been detected in virtually all mammalian tissues, including the brain. Although the regulation of its endogenous levels is not yet fully understood, several studies indicate that PEA concentrations rise in response to tissue injury and cellular stress. This supports the notion that PEA functions as an intrinsic protective agent, mobilized to restore local homeostasis and counteract inflammation. For instance, in response to cellular damage or tissue injury, macrophages, mast cells, and keratinocytes are known to release PEA as part of the body's natural response to mitigate inflammation and promote healing.

The ALIAmide Concept

This endogenous production characteristic suggests a potential physiological role for PEA as a homeostatic regulator, involved in the body's natural processes to resolve inflammation and pain signaling. It is considered an "autocoid local injury antagonist" (ALIAmide), produced on demand in response to tissue injury or inflammation. The ALIAmide parent molecule, palmitoylethanolamide (PEA), is locally produced on demand from a cell membrane precursor in order to control immune-inflammatory cell responses, avert chronic non-resolving inflammation, and limit the resulting clinical signs.

Primary Mechanism: PPAR-α Activation

PEA exerts most of its biological effects in the body secondary to the activation of peroxisome proliferator-activated receptor-α (PPAR-α), but PPAR-α-independent pathways involving other receptors (Transient Receptor Potential Vanilloid 1 [TRPV1], GPR55) have also been identified.

Anti-inflammatory effects of PEA have been associated with PPAR-α activation, a nuclear receptor fundamental in the control of inflammatory responses and expressed in various cells of the immune system. PEA does not elicit anti-inflammatory effects in mutant PPAR-α null mice (PPAR-α−/−). Indeed, when assessed in either the carrageenan hindpaw or phorbol ester ear pinna tests, PEA reduced inflammation in wild-type, but not in PPAR-α−/−, mice.

Entourage Effect and Endocannabinoid Modulation

Several mechanisms underlie PEA's actions, among which the "entourage" effect, consisting of PEA potentiation of endocannabinoid signaling at either cannabinoid receptors or transient receptor potential vanilloid type-1 (TRPV1) channels. PEA's entourage effect enhances the physiological effects of endocannabinoids such as AEA by preventing their enzymatic-mediated hydrolysis by fatty acid amide hydrolase (FAAH), which results in TRPV1 and CB2 stimulation. This provides another route to the activation of macrophages, neutrophils and other immune cells, contributing to PEA's anti-infective properties.

CB2 Receptor Upregulation

PEA was found to increase CB2 mRNA and protein expression through peroxisome proliferator-activated receptor-α (PPAR-α) activation. This novel gene regulation mechanism was demonstrated through pharmacological PPAR-α manipulation, PPAR-α mRNA silencing, and chromatin immunoprecipitation.

Multi-Target Pleiotropic Profile

PEA has been shown to act on several targets, including GPR55, transient receptor potential vanilloid type-1 (TRPV1) channels, fatty acid amide hydrolase (FAAH), and peroxisome proliferator-activated receptor-α (PPAR-α). PEA acts through multiple signaling pathways, including direct activation of GPR55 and PPAR-α, and indirect modulation of TRPV1 channels and CB2 receptors via PPAR-α-dependent mechanisms. PEA may also enhance endocannabinoid signaling by elevating anandamide (AEA) and 2-arachidonoylglycerol (2-AG), contributing to the so-called "entourage effect."

The endogenous fatty acid amide palmitoylethanolamide (PEA) has been shown to exert anti-inflammatory actions mainly through inhibition of the release of pro-inflammatory molecules from mast cells, monocytes, and macrophages.

PEA "Exhaustion" in Chronic Disease

When pain is protracted, PEA "exhaustion" may develop. Chronic inflammatory conditions create lower levels of PEA. The exogenous administration of PEA may in such cases serve to replenish levels of endogenous PEA, restoring its protective, anti-inflammatory and analgesic effects.

4. Scientific Evidence by Area of Use

4.1 Chronic Pain (General)

A systematic review and meta-analysis was undertaken to examine the efficacy of PEA as an analgesic agent for chronic pain. A systematic literature search was performed, using the databases MEDLINE and Web of Science, to identify double-blind randomized controlled trials comparing PEA to placebo or active comparators in the treatment of chronic pain. All articles were independently screened by two reviewers. The primary outcome was pain intensity scores, for which a meta-analysis was undertaken using a random effects statistical model.

The results of this systematic review and meta-analysis suggest that PEA is an effective and well-tolerated treatment for chronic pain. Further study is warranted to determine the optimal dosing and administration parameters of PEA for analgesic effects in the context of chronic pain.

Most clinical studies that have shown decreased chronic pain have used the Normast® brand of ultramicronized PEA at doses of 600 mg twice daily. For neuropathic pain, micronized or ultramicronized PEA treatment (mostly 1200 mg/day, Normast®) for 30–365 days elicited a progressive reduction of pain intensity compared to control. The magnitude of pain reduction with PEA was 1.04 points every 2 weeks (on a 10-point scale). The control group, on the other hand, only had a reduction of 0.20 points every 2 weeks.

Limitations: Results obtained for a total of 933 patients demonstrated the efficacy of PEA over control (p < 0.00001), in particular in six studies apart from the two randomized, double-blind clinical trials included. However, the results are downgraded due to the high heterogeneity of the studies (I² = 99%), and the funnel plot suggests publication bias. Efficacy in achieving a reduction in the need for rescue medications and improvement in functioning, neuropathic symptoms, and quality of life are reported. Therefore, adequately powered randomized, double-blind clinical trials are needed to deepen the domains of efficacy of add-on therapy with PEA for chronic pain.

4.2 Neuropathic Pain

Palmitoylethanolamide has been demonstrated to bind to PPAR-α and performs a great variety of biological functions related to chronic and neuropathic pain and inflammation, as demonstrated in clinical trials. These include peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, postherpetic neuralgia, and vaginal pains.

A well-conducted double-blind multicentre study compared ultramicronized PEA (2 × 600 mg) and placebo as add-on treatments in 73 patients with neuropathic pain following spinal cord injury. Over the 12-week period, no superiority over placebo was seen. This null result in spinal cord injury-related neuropathic pain illustrates that the evidence base is not uniformly positive across all neuropathic pain subtypes.

PEA has been investigated in preclinical models of inflammatory and neuropathic pain, and its efficacy has been demonstrated in clinical conditions including osteoarthritis and joint pain, neuropathic pain, post-operative pain, fibromyalgia, and endometriosis.

4.3 Diabetic Peripheral Neuropathy

One study aimed to determine whether an enhanced bioavailable formulation of PEA was safe, tolerable, and effective for managing diabetic peripheral neuropathy (DPN)-related pain, as well as effective in reducing inflammation and improving quality of life associated with DPN, over an 8-week study period in patients diagnosed with diabetes. The clinical study was an interventional, single-centre, prospective, randomized, quadruple-blinded, placebo-controlled, parallel study investigating the safety, tolerability, and efficacy of a PEA formulation on neuropathic pain. The secondary outcomes of improvement in inflammation markers and sleep quality and improved quality of life when administered as an adjunct analgesic to diabetic medications were also measured over 8 weeks.

4.4 Carpal Tunnel Syndrome

One study investigated the clinical and electrophysiological effects of conservative treatment with PEA in low-to-moderate carpal tunnel syndrome (CTS). A prospective double-blinded randomized study was performed on 61 patients with a clinically and electrophysiologically confirmed diagnosis of low and moderate CTS. The patients were randomly assigned to two groups. Group N was given 300 mg of PEA twice a day over 60 days and Group P received a placebo with exactly the same appearance every 12 hours for the same period.

The results of this study suggest that treatment of CTS with PEA at a dose of 600 mg/day is not associated with an improvement of any clinical and electrophysiological parameters. However, an improvement in the functional status scale (FSS) in the Boston Questionnaire was observed after treatment with PEA. Together with the results of other studies, the authors conclude that further studies of PEA in CTS at higher doses are necessary.

4.5 Endometriosis and Chronic Pelvic Pain

Clinical trials have already demonstrated the beneficial effect of PEA plus polydatin or transpolydatin, in the treatment of secondary dysmenorrhea associated with endometriosis. The evidence in this area derives principally from open-label and pilot studies; adequately powered double-blind RCTs specifically for endometriosis-associated pain remain limited as of the most recent reviews.

4.6 Influenza and Upper Respiratory Tract Infections

PEA was already identified in the 1950s as a therapeutic substance with potent anti-inflammatory properties. Since 1970, the anti-inflammatory and other immune-modulating properties of PEA have been shown in a number of placebo-controlled double-blind clinical trials on influenza and common cold. Positive results coincided with the clinical use of PEA in former Czechoslovakia under the brand name Impulsin®.

Studies published by Masek and colleagues (1974) found subjects supplemented daily with 1800 mg of PEA for 12 days showed a reduction in episodes of fever, sore throat, and headaches compared to placebo groups. Masek and colleagues also showed that PEA prophylactic supplementation for 8 weeks resulted in a decrease in the incidence of cold and flu from 40% to 32%. A study conducted by Plesnik and colleagues (1977) showed children supplemented daily with 600 mg of PEA had a lower occurrence of acute respiratory tract infections compared with a placebo.

All five clinical trials pointed towards the same conclusion, i.e., that PEA had clear treatment effects in respiratory tract infections, and that it could be used safely as prophylaxis against influenza. Previous human clinical studies indicated that PEA is an effective treatment in reducing cold and flu symptoms, but these studies are almost 50 years old. Updated trials using modern micronized formulations are needed to confirm these findings with contemporary methodological standards.

4.7 Neuroinflammatory and Neurodegenerative Conditions

Considering the growing scientific evidence on the role of PEA in modulating inflammation and pain, several communications aim to summarize its key mechanisms of action in neurological disease. Endocannabinoid signaling and endocannabinoid-related compounds have been demonstrated to modulate the main pathological processes during early Alzheimer's disease (AD), including protein misfolding, neuroinflammation, excitotoxicity, mitochondrial dysfunction, and oxidative stress. Among these compounds, PEA has attracted much attention because it exerts a local anti-injury function through a down-modulation of mast cells and protects neurons from excitotoxicity through several mechanisms.

Preclinical studies indicate that PEA, especially in micronized or ultramicronized forms (formulations that maximize PEA bioavailability and efficacy), could be a potential therapeutic agent for the effective treatment of different pathologies characterized by neurodegeneration, (neuro)inflammation, and pain. In particular, the potential neuroprotective effects of PEA have been demonstrated in several experimental models of Alzheimer's disease. Interestingly, a single-photon emission computed tomography (SPECT) case study reported that a mild cognitive impairment (MCI) patient, treated for 9 months with ultramicronized-PEA/luteolin, presented an improvement of cognitive performances. This constitutes very preliminary human evidence (a single case study), and controlled clinical trials in AD or MCI populations are needed.

4.8 Neuropsychiatric Sequelae of COVID-19

PEA is an anti-inflammatory and neuroprotective amide used in depressive syndromes. One study investigated whether micronized/ultramicronized (m/um) PEA improves neuropsychiatric sequelae in COVID-19 survivors. Patients evaluated at a post-COVID-19 outpatient clinic between February and August 2021 presenting neuropsychiatric manifestations (n = 98) were offered treatment with m/umPEA 600 mg twice daily for 3 months. Those accepting m/umPEA therapy (n = 57) were compared with those who did not (n = 41) in terms of depression, fatigue, chronic pain, and subjective well-being through validated scales. The two groups did not differ in terms of demographics, comorbidities, psychiatric history, antidepressant therapy, acute COVID-19 severity, or baseline neuropsychiatric status. This was an observational, non-randomized comparison and therefore constitutes preliminary evidence only.

4.9 Broader Spectrum of Investigated Conditions

Identified RCTs have explored the effect of PEA supplementation on a heterogeneous group of illnesses including: (i) neuropsychiatric disturbances; (ii) sensory and/or motor neurological disturbances; and additional conditions in other domains. Because of its multiple molecular targets and mechanisms of action, PEA has demonstrated therapeutic benefits in various diseases, including neurological, psychiatric, ophthalmic, metabolic, oncological, renal, hepatic, immunological, rheumatological, and gastrointestinal conditions. It must be noted, however, that for most of these categories outside pain, the evidence base derives predominantly from preclinical or observational studies rather than large double-blind RCTs.

There is a significant number of prospective and randomized trials demonstrating the pain-relieving effects of PEA. There is lesser evidence of benefit in patients with nonpain symptoms related to depression, Parkinson disease, strokes, and autism.

5. Body Systems and Health Areas Associated with PEA

• Peripheral and Central Nervous System: PEA is naturally present in the CNS and has antinociceptive properties in several animal models. It also prevents neurotoxicity and neurodegeneration and inhibits peripheral inflammation.
• Immune System / Mast Cell Regulation: PEA has been shown to exert anti-inflammatory actions mainly through inhibition of the release of pro-inflammatory molecules from mast cells, monocytes, and macrophages.
• Musculoskeletal System: PEA's efficacy has been demonstrated in clinical conditions including osteoarthritis and joint pain and fibromyalgia.
• Reproductive / Gynecological System: Clinical trials have already demonstrated the beneficial effect of PEA plus polydatin or transpolydatin, in the treatment of secondary dysmenorrhea associated with endometriosis.
• Gastrointestinal System: It is now established that PEA is biosynthesized to maintain cellular homeostasis when this is challenged by external stressors provoking inflammation, neuronal damage, and pain. PEA acts via several targets, including cannabinoid CB1 and CB2 receptors, TRPV1 ion channels, PPAR-α, and orphan GPR55, all involved in the control of intestinal inflammation.
• Respiratory System: PEA was already identified in the 1950s as a therapeutic substance with potent anti-inflammatory properties. Since 1970, the anti-inflammatory and other immune-modulating properties of PEA have been shown in a number of placebo-controlled double-blind clinical trials on influenza and common cold.
• Skin / Allergic Conditions: Allergic reactions such as allergic rhinitis, allergic dermatitis and allergic asthma are characterized by inflammation and inflammatory cell infiltration, and PEA's mast-cell-modulating properties are relevant to these conditions.
• Broader Multi-System Role: Various molecular studies have verified that PEA has numerous actions, including strong anti-inflammatory and pain-relieving effects, anticonvulsant effects, antimicrobial effects, antiepileptic effects, immunomodulatory effects, and neuroprotective effects. Because of its multiple mechanisms of action, PEA may provide therapeutic benefits in many diseases across various body systems, including neurology, psychiatry, ophthalmology, metabolic disorders, oncology, renal, hepatic, immune, joint, and gut.

6. Dosage Forms and Dosages Reported in Studies

PEA is generally considered to have a favorable safety profile with few reported adverse effects at typical dosages ranging from 300 mg to 1200 mg per day, often given as 300 mg or 600 mg twice daily.

PEA-containing products are typically administered at a recommended daily dosage of 1200 mg.

The following specific dosages have been reported in published clinical studies:

• Most clinical studies that have shown decreased chronic pain have used the Normast® brand of ultramicronized PEA at doses of 600 mg twice daily.
• Studies published by Masek and colleagues (1974) found subjects supplemented daily with 1800 mg of PEA for 12 days showed a reduction in episodes of fever, sore throat, and headaches.
• A study conducted by Plesnik and colleagues (1977) showed children supplemented daily with 600 mg of PEA had a lower occurrence of acute respiratory tract infections.
• In a carpal tunnel syndrome RCT, Group N was given 300 mg of PEA twice a day over 60 days.
• In a post-COVID-19 neuropsychiatric study, patients were offered treatment with m/umPEA 600 mg twice daily for 3 months.
• In a double-blind multicentre study in spinal cord injury patients, the dose used was ultramicronized PEA 2 × 600 mg daily.

The six published randomized clinical trials are of variable quality. Presentation of data without information on data spread and nonreporting of data at times other than the final measurement were among issues that were identified. The clinical data are clearly promising, but more clinical trials are necessary, ideally with publicly available study protocols. Study size, treatment lengths, and choice of scales for primary outcome measures are all important considerations, as well as head-to-head comparisons of unmicronized versus micronized formulations of PEA and comparisons versus standard treatments.

7. Safety Considerations and Interactions

General Safety Profile

PEA's long-established safety profile, supported by both clinical and preclinical research dating back to the 1950s, further reinforces its potential as a valuable adjunctive therapy for managing chronic health conditions.

For treatment times up to 49 days, the current clinical data argue against serious adverse drug reactions (ADRs) at an incidence of 1/200 or greater. For treatment lasting more than 60 days, the number of patients is insufficient to rule out a frequency of ADRs of less than 1/100.

Across more than 20 clinical trials involving nearly 2,000 patients, no serious side effects have been reported. The rare adverse events that do show up, such as mild stomach discomfort or brief palpitations, affect a very small number of people and tend to resolve quickly on their own.

Mechanism Underlying Safety

One of the main reasons PEA causes so few problems is that the body already produces it. PEA is produced naturally in cells from fatty building blocks in cell membranes, and it gets broken down by two dedicated enzymes into palmitic acid and ethanolamine, both of which are ordinary substances the body handles every day.

Preclinical Toxicity Data

Animal toxicity studies push the safety margin much further. In a prenatal developmental toxicity study conducted under international guidelines, pregnant rats received up to 1,000 mg per kilogram of body weight daily with no adverse effects on the mothers, embryos, or fetuses. Converted to a human equivalent dose, that translates to more than 9.7 grams per day, roughly 10 to 30 times the doses used in human supplements. No signs of organ damage, hormonal disruption, or developmental harm appeared at any dose level tested.

Drug Interactions

There are no reported drug-drug interactions and very few reported adverse effects from PEA.

No drug interactions with PEA have been documented. In clinical case series, PEA has been combined with common pain medications including tramadol, pregabalin, gabapentin, and duloxetine without any adverse interactions or added discomfort.

Based on its mechanism, PEA may be considered likely to interact with other PPAR-α agonists used to treat high triglycerides; this remains unconfirmed.

Limitations of the Long-Term Safety Data

For treatment lasting longer than 60 days, fewer patients have been studied, so the data can only rule out serious reactions occurring in more than 1 in 100 people. That gap is a limitation of the existing research rather than a red flag.

Formulation Quality and Standardization

PEA's status as a supplement raises potential issues regarding product quality, purity, and standardization across different formulations (e.g., micronized, ultramicronized). There are no head-to-head clinical comparisons of unmicronized versus micronized formulations of PEA, and so evidence for superiority of one formulation over the other is currently lacking. Nevertheless, the available clinical data support the contention that PEA has analgesic actions and motivate further study of this compound.

References

• Palmitoylethanolamide, an endogenous fatty acid amide, and its pleiotropic health benefits: A narrative review (PMC12239978)
• Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation (PMC12189779)
• Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials (PMC10053226)
• Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence (PMC9414729)
• Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy (PMC5094513)
• The Basal Pharmacology of Palmitoylethanolamide (PMC7662788)
• Palmitoylethanolamide: A Natural Compound for Health Management (PMC8157570)
• Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold (PMC3771453)
• Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical (PMC3744360 / Tandfonline)
• Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor (PMC5428303)
• Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent (PMC4280974)
• Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain (PMC4171547)
• Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism (PMC3596927)
• Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's Disease (PMC6667638)
• Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in COVID-19 survivors (PMC11424064)
• Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study (PMC5685977)
• A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain (PMC9700575)
• The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection — A Double Blind, Randomised, Placebo-Controlled Trial (PMC10609976)
• Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's Disease (PMC8511319)
• Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis (PMC11174044)
• Palmitoylethanolamide — an overview (ScienceDirect Topics)
• Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations (ScienceDirect 2024)
• The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review (PubMed 31113223)
• Palmitoylethanolamide (PEA) — Cognitive Vitality For Researchers (Alzheimer's Drug Discovery Foundation)
• Palmitoylethanolamide — WikiMSK